Scholarlink

<p>Long noncoding RNAs (lncRNAs), defined as noncoding transcripts exceeding 200 nucleotides without protein-coding potential, have been increasingly recognized for encoding polipeptides or proteinsimplicated in the regulation of malignant tumor initiation, progression, and prognosis. Among them, small nucleolar RNA host gene 29 (SNHG29) has attracted increasing attention because of its aberrant expression across diverse malignancies. This report reviews the latest research regarding its expression patterns, regulatory functions, and involved signaling pathways. This review synthesizes current insights into the contributions of SNHG29 to oncogenic processes, including cell proliferation, migration, epithelial‒mesenchymal transition, chemoresistance, and immunosuppression. Furthermore, evidence indicates that SNHG29 functions as a competing endogenous RNA (ceRNA), modulating tumor progression via the miRNA‒mRNA axis and signaling pathways such as the ATR‒Chk1, PI3K‒AKT, and Wnt‒β-catenin pathways. Cumulative data position SNHG29 as a promising diagnostic and prognostic biomarker, as well as a potential molecular target for therapeutic intervention in various malignancies.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

The role of long noncoding RNA SNHG29 in malignant tumors

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年7月15日

查看全文
  • Tingcheng Bu,
  • Wendong Gu,
  • Yingjie Shao

摘要

Long noncoding RNAs (lncRNAs), defined as noncoding transcripts exceeding 200 nucleotides without protein-coding potential, have been increasingly recognized for encoding polipeptides or proteinsimplicated in the regulation of malignant tumor initiation, progression, and prognosis. Among them, small nucleolar RNA host gene 29 (SNHG29) has attracted increasing attention because of its aberrant expression across diverse malignancies. This report reviews the latest research regarding its expression patterns, regulatory functions, and involved signaling pathways. This review synthesizes current insights into the contributions of SNHG29 to oncogenic processes, including cell proliferation, migration, epithelial‒mesenchymal transition, chemoresistance, and immunosuppression. Furthermore, evidence indicates that SNHG29 functions as a competing endogenous RNA (ceRNA), modulating tumor progression via the miRNA‒mRNA axis and signaling pathways such as the ATR‒Chk1, PI3K‒AKT, and Wnt‒β-catenin pathways. Cumulative data position SNHG29 as a promising diagnostic and prognostic biomarker, as well as a potential molecular target for therapeutic intervention in various malignancies.